<DOC>
	<DOCNO>NCT00637104</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness TiN-coated MAR-Tyn stent maintain minimum lumen diameter de novo native coronary artery lesion compare uncoated control cobalt-chromium balloon-expandable stent ( Vision , Abbott Vascular ) . Both stent mount Rapid Exchange Stent Delivery System .</brief_summary>
	<brief_title>European Multicenter , Randomized , Comparative Efficacy/Safety Study Mar-Tyn TiN-Coated Stent</brief_title>
	<detailed_description>Occlusive coronary artery disease predominantly cause coronary atherosclerosis , pathologic vascular condition characterize abnormal lipid fibrous tissue accumulation vessel wall . This condition may accompany degenerative change and/or calcification lead stenosis ( narrow ) luminal channel . Percutaneous Transluminal Coronary Angioplasty ( PTCA ) well-accepted method non-surgical myocardial revascularization select patient symptomatic occlusive coronary artery disease . Restenosis important challenge limit long-term success coronary angioplasty . Symptomatic restenosis usually occur 6 month angioplasty procedure . The rate restenosis report numerous clinical trial vary 13 % 57 % . This variability may attribute part difference method use assess occurrence restenosis criterion use define restenosis . Regardless exact percentage , restenosis remain Achilles heel angioplasty . Numerous pharmaceutical approach limit restenosis test , none successful date . It choose coat stent Titanium Nitrate ( TiN ) , inert , biocompatible material , create thin physical barrier diffusion toxic metal atom , TiN create smooth surface impossible obtain metal alloy . This coat applied cobalt chromium platform , `` Numen '' , make L605 Cobalt-20 Chromium-15 Tungsten-10 Nickel alloy . This alloy contain low Nickel percentage Cobalt Chromium alloy used surgical implant . The strut thickness platform reduce minimum 65 micron optimal hemodynamic performance permit ultra low profile delivery system . The `` Numen '' design comply requirement `` LMS -Less Mismatch Stent '' theory apply multiple 1 mm high zigzag form stent pattern align segment 45° respect blood flow stent expand nominal diameter . TiN coat use commercially hard-wearing chemical inactive property , particularly surgical tool . TiN feature chemical stability , great hardness , excellent wear property , low electric impedance , biocompatibility , hemocompatibility possibility , application process , exchange orientation grain , hardness , wear characteristic also biocompatibility ( nanocrystalline structure produce chemical surface suitable endothelial cell ) . The produced coating fine grain dense porosity within film structure le 10 nm diameter . Furthermore , iliac artery stent model normal rabbit , safety efficacy reduce restenosis TiN coat Numen™ stent assess . The special TiN coat Mar-Tyn stent promise reduce lesion cause intima neoplasia . This study multicenter ( 8 European center ) , prospective , randomized single blind study . This study 2-arm design assess safety effectiveness Tin-coated MAR-Tyn stent uncoated control cobalt-chromium balloon-expandable stent ( Vision , Abbott Vascular ) , mount Rapid Exchange Stent Delivery System . A total 160 patient enter study randomize 1:1 basis . Patients meet eligibility criterion either randomize Treatment A Treatment B . The patient know stent implanted physician unblinded . Patients follow 30 day , 6 , 12 month post-procedure , patient undergo repeat angiography 6 month . All adverse event 1 year follow-up period collect analyzed .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Tin</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>Patients must meet ALL follow criterion : 1 . The patient must &gt; 18 year age ; 2 . Female childbearing potential must negative pregnancy test within 7 day enrollment utilize reliable birth control eight month enrollment 3 . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , III ) OR patient document silent ischemia ; 4 . Single treatment de novo lesion major coronary artery patient single multivessel disease ; patient multiple lesion include lesion require treatment ; 5 . Target vessel diameter lesion site &gt; 2.50mm &lt; 3.5mm diameter ( visual estimate ) ; 6 . Target lesion &gt; 10mm &lt; 22mm length ( visual estimate ) ; 7 . Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; 8 . At least TIMI II coronary flow ; 9 . Acceptable candidate coronary artery bypass surgery ( CABG ) ; 10 . Patient willing comply specify followup evaluation ; 11 . Patient must provide write informed consent prior procedure use form approve local Ethics Committee . 12 . Patient pretreated aspirin clopidogrel , alternatively , aspirin alone plus load dose 300 mg clopidogrel procedure completion case urgent PCI Patients exclude ANY follow condition apply : 1 . Patient experience Qwave nonQwave myocardial infarction document total CK &gt; 2 time normal within precede 24 hour CK CKMB enzymes remain normal time treatment ; 2 . Has unstable angina classified Braunwald III B C A IIIIII , peri infarction ; 3 . Unprotected leave main coronary disease &gt; 50 % stenosis ; 4 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede runoff ; 5 . Have ostial target lesion ; 6 . Have target lesion venous graft ; 7 . Angiographic evidence thrombus within target lesion ; 8 . Calcified lesion successfully predilated ; 9 . Documented leave ventricular ejection fraction &lt; =25 % ; 10 . Totally occluded vessel ( TIMI 0 level ) ; 11 . Impaired renal function ( creatinine &gt; 3.0 mg/dl ) time treatment ; 12 . Pretreatment device balloon angioplasty ; 13 . Target lesion excessive tortuousity angulation ( &gt; 45° ) make unsuitable stent delivery deployment ; 14 . Target lesion involve bifurcation include diseased side branch &gt; =2 mm diameter ( either stenosis main vessel major branch stenosis major branch ) would require side branch stenting ; 15 . Prior stent within 5mm target lesion ; 16 . Direct Stenting 17 . Recipient heart transplant ; 18 . Patient life expectancy le 12 month ; 19 . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix ) ticlopidine ( Ticlid ) , heparin , cobalt , chromium , contrast agent ( manage medically ) 20 . Recent ( 6 month ) cerebrovascular accident intracranial hemorrhage 21 . Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; 22 . Currently participate investigational drug another device study ; 23 . Intervention another lesion occur within 6 month index procedure ; 24 . In investigator 's opinion , lesion suitable stenting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>percutaneous transluminal coronary angioplasty</keyword>
	<keyword>stent</keyword>
	<keyword>restenosis</keyword>
	<keyword>biocompatible material</keyword>
	<keyword>ceramic</keyword>
</DOC>